BridgeBio Pharma
Stock Forecast, Prediction & Price Target
BridgeBio Pharma Financial Estimates
BridgeBio Pharma Revenue Estimates
BridgeBio Pharma EBITDA Estimates
BridgeBio Pharma Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $69.71M N/A | $77.64M 11.37% | $9.30M -88.01% | Avg: $249.54M Low: $120.12M High: $520.35M avg. 2582.38% | Avg: $553.90M Low: $337.30M High: $1.09B avg. 121.96% | Avg: $1.14B Low: $695.10M High: $2.25B avg. 106.07% | Avg: $1.88B Low: $1.14B High: $3.71B avg. 64.77% |
Net Income
% change YoY
| $-639.29M N/A | $-493.96M 22.73% | $-643.20M -30.21% | Avg: $-526.38M Low: $-616.97M High: $-78.13M avg. 18.16% | Avg: $-306.03M Low: $-564.88M High: $39.06M avg. 41.85% | Avg: $-29.95M Low: $-67.90M High: $-14.72M avg. 90.21% | Avg: $490.81M Low: $241.31M High: $1.11B avg. 1738.58% |
EBITDA
% change YoY
| $-539.67M N/A | $-353.67M 34.46% | $-565.46M -59.88% | Avg: $-249.54M Low: $-520.35M High: $-120.12M avg. 55.86% | Avg: $-553.90M Low: $-1.09B High: $-337.30M avg. -121.96% | Avg: $-1.14B Low: $-2.25B High: $-695.10M avg. -106.07% | Avg: $-1.88B Low: $-3.71B High: $-1.14B avg. -64.77% |
EPS
% change YoY
| -$4.43 N/A | -$3.35 24.37% | -$3.95 -17.91% | Avg: -$2.93 Low: -$3.79 High: -$0.48 avg. 25.90% | Avg: -$1.85 Low: -$3.47 High: $0.24 avg. 36.96% | Avg: -$0.18 Low: -$0.42 High: -$0.09 avg. 90.02% | Avg: $3.02 Low: $1.48 High: $6.84 avg. 1738.58% |
Operating Expenses
% change YoY
| $646.34M N/A | $546.08M -15.51% | $614.22M 12.47% | Avg: $2.03B Low: $979.66M High: $4.24B avg. 231.31% | Avg: $4.51B Low: $2.75B High: $8.91B avg. 121.96% | Avg: $9.30B Low: $5.66B High: $18.38B avg. 106.07% | Avg: $15.33B Low: $9.34B High: $30.28B avg. 64.77% |
FAQ
What is BridgeBio Pharma stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 472.20% in 2025-2028.
We have gathered data from 9 analysts. Their low estimate is -616.97M, average is -526.38M and high is -78.13M.
What is BridgeBio Pharma stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 718.80% in 2025-2028.
We have gathered data from 9 analysts. Their low revenue estimate is $120.12M, average is $249.54M and high is $520.35M.
What is BridgeBio Pharma stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 472.86% in 2025-2028.
We have gathered data from 9 analysts. Their low earnings per share estimate is -$3.79, average is -$2.93 and high is $-0.48.
What is the best performing analyst?
In the last twelve months analysts have been covering BridgeBio Pharma stock. The most successful analyst is David Lebowitz.